Erythropoiesis Stimulating Agents and Tumor Progression (R01)
The summary for the Erythropoiesis Stimulating Agents and Tumor Progression (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Erythropoiesis Stimulating Agents and Tumor Progression (R01): -Purpose. This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites applications for research projects that investigate the effects of Erythropoietin (EPO) on tumor cell growth. EPO has been widely used to relieve the anemia associated with renal failure. In addition, EPO and other erythropoiesis stimulating agents (ESAs) have recently been used to treat the anemia associated with cancer chemotherapy. However, several clinical trials involving administration of ESAs, have suggested that ESAs may accelerate tumor progression and increase mortality in cancer patients. It is therefore important to understand the biology of ESAs on tumor cell growth and apoptosis. The purpose of this FOA is to stimulate high quality research on the effects of ESAs on tumor cell biology and tumor progression. -Mechanism of Support. This FOA uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-024 that encourages applications under the NIH Exploratory/Developmental (R21) Grant mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
|Federal Grant Title:||Erythropoiesis Stimulating Agents and Tumor Progression (R01)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||PA-09-023|
|Type of Funding:||Grant|
|CFDA Descriptions:||Cancer Cause and Prevention Research|
|Current Application Deadline:||Jan 07, 2012|
|Original Application Deadline:||Jan 07, 2012|
|Posted Date:||Nov 06, 2008|
|Creation Date:||Nov 06, 2008|
|Archive Date:||Feb 07, 2012|
|Total Program Funding:|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
- Similar Government Grants
- • Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinic...
- • U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers ...
- • Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancrea...
- • Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis,...
- • Cancer Intervention and Surveillance Modeling Network (CISNET) (U01 Clinical Trial Not All...
- • Pilot Studies in Pancreatic Cancer
- • Cancer Prevention Research Small Grant Program
- • Molecular Targets for Nutrients in Prostate Cancer Prevention
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...